Synapsoft logo
AI Insights from Disclosures
Searching...
NKGen Biotech Korea Co., Ltd. 182400
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
NKGen Biotech Korea Co., Ltd. commenced rehabilitation proceedings through the Seoul Bankruptcy Court in June 2024, and the rehabilitation proceedings were concluded on September 4, 2025, with NKGen Biotech, Inc. designated as the final acquirer. The company subsequently changed its name to NKGen Biotech Korea Co., Ltd.
Representative Director Kim Yongman
Founded January 14, 2002
Corporation Type KOSDAQ
Industry Classification Manufacture of medicinal chemicals
Corporate number 11011-2421157
Business number 206-81-66254
Phone Number 031-603-9218
Fax Number 031-8017-8124
Website www.nkmax.com
Company Address 440 Changnyong-daero, Yeongtong-gu, Suwon-si, Gyeonggi-do
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant